Crucell Cuts a Good Bargain
Executive Summary
J&J Centocor's deal with Crucell demonstrates how large pharma companies are being forced to make bigger sacrifices in return for potential products. Centocor is believed to be paying just $2 million, with $1-2 million in annual fees but the deal value could reach $100 million and give J&J an opportunity to strengthen its oncology product line. And Crucell gets closer to its goal of being a product company without taking on all the risks of drug development.You may also be interested in...
Crucell Falls Back on Vaccines
Forced by a series of setbacks to downsize its antibody platform, Crucell is now turning to vaccine applications of its human cell production technology to satisfy its product developer ambitions.
J&J/Centocor: One Rx Treats a Range of Growth Ailments
Acquiring Centocor gives J&J products to help fill the void in its drug portfolio. Will it also use Centocor's core biologics expertise to launch a broader move into biotechnology?
Teva Boss Delights In European Progress
Ongoing launches, relatively stable market conditions and cost-cutting initiatives are producing record profits from Teva’s European operations, president and CEO Kåre Schultz told delegates to a J.P. Morgan Healthcare Conference.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports